Back to the top

Missed Opportunities to Prevent Ovarian Cancer During Unrelated Surgeries | MedPage Today

Missed Opportunities to Prevent Ovarian Cancer During Unrelated Surgeries by Charles Bankhead, Senior Editor, MedPage Today August 14, 2025 • 4 min read Salpingectomy often omitted during surgery for permanent contraception, other procedures Key Takeaways Genetic susceptibility accounts for 20% of ovarian cancer risk, and risk-reducing bilateral salpingectomy remains the gold standard for prevention. In this study, about 24% of patients with high-grade serous ovarian cancer had missed opportunities for risk-reducing surgery before cancer diagnosis. Among the women with a first-degree family history of ovarian cancer, 43.2% had mutations that increased susceptibility to ovarian cancer. Read More at MedPage Today...

Continue reading

To prevent ovarian cancers, fallopian tube removal is on the rise | STAT

To prevent ovarian cancers, fallopian tube removal is on the rise There’s long been confusion between ‘tube-tying’ and salpingectomy. Now, oncologists are trying to dispel it June 16, 2025 To Rebecca Stone, the single most important fact about ovarian cancer is that it’s usually a misnomer. The most common kind — responsible for 70% of cases and 90% of deaths — often has its silent beginnings not in the ovary, but in the fallopian tube. This isn’t just an interesting factoid; as a gynecologic oncologist at Johns Hopkins, Stone sees it as a reason to evangelize. There’s no way to......

Continue reading

I had one simple surgery to lower my risk of the deadliest cancer for women. Here’s why you probably don’t know about it—but should | Fortune Well

I had one simple surgery to lower my risk of the deadliest cancer for women. Here’s why you probably don’t know about it—but should June 16, 2025 I woke up from surgery groggy, with three minuscule incisions in my abdomen and huge peace of mind. I’d just had my fallopian tubes laparoscopically removed, as it’s the best—and possibly only—defense against ovarian cancer, which, though rare, is the most lethal gynecological cancer there is. Read More at Fortune Well...

Continue reading

New Blood-Based Technology Tracks Tumor Evolution in Ovarian Cancer Patients

New Blood-Based Technology Tracks Tumor Evolution in Ovarian Cancer Patients Break Through Cancer researchers uncover hidden cell populations driving relapse — findings could pave the way for more targeted treatments News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) October 01, 2025 – A new study published in Nature uncovers how ovarian cancers evolve during treatment, and how blood samples taken throughout disease progression could help guide therapies more effectively. The research shows that drug-resistant cancer cell populations may exist long before treatment begins, and that tracking these populations over time can reveal vulnerabilities that may be......

Continue reading

American Cancer Society and Break Through Cancer Unite to Outsmart Ovarian Cancer

American Cancer Society and Break Through Cancer Unite to Outsmart Ovarian Cancer In recognition of Ovarian Cancer Awareness Month, two leading cancer research organizations to collaborate to bring decades of scientific research into clinical practice News Release For Immediate Release Media Contact: Michele Money-Carson, Michele.Money-Carson@cancer.org Kari McHugh, kari.mchugh@breakthroughcancer.org ATLANTA, September 25, 2025 – More than 20,000 new cases of ovarian cancer will be diagnosed in the United States this year, and more than 12,000 women are expected to die from the disease. Today, the American Cancer Society (ACS) and Break Through Cancer are announcing a strategic collaboration that will aim......

Continue reading

Accelerating Discovery: Break Through Cancer’s 2nd Annual Hackathon

Accelerating Discovery: Break Through Cancer’s 2nd Annual Hackathon This June, Break Through Cancer hosted its 2nd Annual Hackathon at the Broad Institute, bringing together 67 participants across seven TeamLabs for two days of intense, cross-disciplinary problem solving. Researchers, clinicians, data coordinators, and Break Through Cancer staff worked side by side to tackle some of the most pressing analytical challenges across glioblastoma, ovarian, and pancreatic cancer.   Radical Collaboration in Action Hackathons are designed to spark innovation by bringing together people who don’t normally sit in the same room. For Break Through Cancer, they are a natural extension of our TeamLab......

Continue reading

Break Through Cancer Launches Largest-Ever Investment in Pediatric Osteosarcoma Research

Break Through Cancer Launches Largest-Ever Investment in Pediatric Osteosarcoma Research Backed by a $15 million investment, families, funders, and researchers unite to advance long-awaited breakthroughs against this deadly childhood bone cancer News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) September 18, 2025 – Supported by patient-driven foundations, eight leading research institutions, including over 20 researchers, and a $15 million dollar investment, Break Through Cancer’s Defying Osteosarcoma TeamLab mobilizes the largest, most unified effort in pediatric osteosarcoma research in North America. While other cancers have benefited from waves of innovation and precision medicine, the standard chemotherapy treatment......

Continue reading

New Study Finds Hidden Disease in Nearly Half of Ovarian Cancer Patients in ‘Remission’

New Study Finds Hidden Disease in Nearly Half of Ovarian Cancer Patients in ‘Remission’ Using minimally invasive surgery and blood tests Break Through Cancer TeamLab found cancer cells, new drug targets, and biological clues for future therapies News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) August 01, 2025 – Survival rates for advanced ovarian cancer have remained stagnant for over four decades, largely because it so often recurs. While patients respond well to initial surgery and chemotherapy, it comes back in 4 out of 5 cases. A new Break Through Cancer study published in Clinical Cancer......

Continue reading

Can Early Intervention Prevent Leukemia? New Trial Gives Patients a Choice Beyond the Current ‘Wait and See’ Approach

Can Early Intervention Prevent Leukemia? New Trial Gives Patients a Choice Beyond the Current ‘Wait and See’ Approach Scientists are exploring if early intervention can prevent AML in high-risk patients, shifting the focus from monitoring to proactive prevention News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) July 10, 2025 – Break Through Cancer, a Boston-based cancer research foundation, has launched a clinical trial to evaluate the feasibility of early intervention for Clonal Hematopoiesis (CH), a precursor to acute myeloid leukemia (AML). This multi-institutional study focuses on high-risk patients, exploring a new approach to managing this pre-malignant......

Continue reading

Break Through Cancer
101 Rogers Street
Suite 3A
Cambridge, MA 02142
Info@breakthroughcancer.org
1-800-757-9881